Chunye Zhang, Ellen Stelloo, Sharon Barrans, Francesco Cucco, Dan Jiang, Maria-Myrsini Tzioni, Zi Chen, Yan Li, Joost F Swennenhuis, Jasmine Makker, Lívia Rásó-Barnett, Hongxiang Liu, Hesham El-Daly, Elizabeth Soilleux, Nimish Shah, Sateesh Kumar Nagumantry, Maw Kyaw, Mahesh Panatt Prahladan, Reuben Tooze, David R Westhead, Harma Feitsma, Andrew J Davies, Catherine Burton, Peter W M Johnson, Ming-Qing Du
MYC translocation occurs in 8-14% of diffuse large B-cell lymphoma (DLBCL), and may concur with BCL2 and/or BCL6 translocation, known as double-hit (DH) or triple-hit (TH). DLBCL-MYC/BCL2-DH/TH are largely germinal centre B-cell like subtype, but show variable clinical outcome, with IG::MYC fusion significantly associated with inferior survival. While DLBCL-MYC/BCL6-DH are variable in their cell-of-origin subtypes and clinical outcome. Intriguingly, only 40-50% of DLBCL with MYC translocation show high MYC protein expression (>70%)...
March 2024: Leukemia